Turkey: Clinical Trials And Technology Development Areas In The Research And Development World

Last Updated: 11 October 2009
Article by E. Sevi Firat and Banu Imadoglu

Research and Development ("R&D") activities are an investment field that has become more of an issue in Turkey in recent years.

In the Pre-Accession Economic Program 2008 Report recently issued by the State Planning Organization, the share of the R&D expenses in the total share of the gross domestic product of Turkey has been ascertained as 0,76 by the year 2006; however, the EU average has been ascertained as 1,84 percent and it has been pointed out that the attempts to improve the R&D activities and innovativeness will continue on 2009-2011, and the given ratio is targeted to be increased up to 2 percent by the year of 2013.

It is beyond dispute that pharmaceutical sector carries utmost importance for the continuance of the R&D activities and in this regard clinical trials are in the scope of R&D activities that must be supported.

According to the data of the Clinicaltrials.gov of September 30, 2009, 79.387 researches is being carried out in 171 countries. Considering that the number of clinical trials carried out domestically by the pharmaceutical companies is about 385.. In this environment knowing the fosterages that are provided to the R&D activities and searching for the ways of making use of these gains importance.


Law numbered 5746 concerning Endorsement of Research and Development Activities ("R&D Law") has been put in to force for the purpose of creating an economical environment of high efficiency and competency by supporting the R&D activities. Under the Law, as of 2004 deduction of 100 percent of the R&D expenses from the tax assessment that the taxpayers has been entitled to pay as per the Corporate Tax and Income Tax Laws has been accepted and it has been stated that the R&D Law will be valid until 2023. The Law also provides income tax stoppage for the R&D personnel, insurance premium and capital support for the entrepreneurs who seek to make investment.

It is incontestable that the clinical trials are R&D activities. However, pursuant to Enforcement and Controlling Regulation Concerning Endorsement of Research and Development Activities ("R&D Regulation") regulating the principles of application for the R&D Law "Clinical trials that has not been conducted within Turkey for at least 2 stages prior to the pharmaceutical manufacture license and clinical trials that are conducted after the manufacture license" has been excluded from the scope of the R&D's. Due to this expression, the clinical trials whose at least two stage is not conducted in Turkey will not be able to benefit from the fosterages provided by the R&D Law.

R&D Regulation, which can be referred as a source by the faculty members who seeks to carry out a clinical trial, constitutes an important step particularly for supporting the R&D activities in Turkey.

Although the concept of R&D became more popular in Turkey with the enforcement of R&D Law in 2008, the concept of R&D has already been in Turkey's agenda since the beginning of 2000 and subjected to several administrative and legal regulations that have been issued for its development. The concept of R&D has been previously defined under the 4691 numbered Technology Development Areas Law ("TDA Law") that has come into force with its establishment in the 6 July 2001 dated Official Gazette. Just like the R&D Law, the TDA Law has been issued on purpose of endorsing R&D activities and investments. The Technology Development Areas ("TDA") that the legal basis for establishment has been provided under the TDA Law, provides to the companies, which have been embodied to carry out R&D activities, various fosterages. As it is known, there are 31 TDA's constructed as of September 2008 and 18 of those constructed are active.

TDAs are the organizations that are professionally administered in the purpose of improving competency and innovativeness of the area, region in the filed of technology and the institutions and enterprises of the country that they are established in general and aim to encourage and help circulation of information and technology between the universities, research centers, companies and market, support establishment and development of innovation based companies, provide high qualified office area and support services to be used by the shareholders in their R&D activities. With regard to this definition, it is possible to say that TDAs are areas that gathers the sources of the establishment area and provides totality to the person who wants to benefit from these sources.

Nowadays, many industrialized country considers TDAs as the most important instrument for technological and economical development. For example; manufacture and service sectors of many countries such as; the United States of America, England, France, Japan, China, Korea, India, Israel, Finland owns a remarkable part of their manufactured added-value to R&D activities conducted within the scope of the TDA's.

It is clear that the pharmaceutical company that seeks to carry out a clinical trial will be in need of necessary equipment, volunteer and experienced academic personnel for clinical trial of their pharmaceutical. TDA may appear to be a center that provides human resource and responding to requirements that may arise in means of logistic support regarding the activities of the companies seeking to carry out clinical trials. Some of the TDAs appear to be appropriate places for clinical trials as they have hospitals and laboratories inside.


In accordance with the TDA Law, business companies and persons active in the area and benefiting from the services and opportunities of the area are defined as "entrepreneurs". A company or person that aims to become an entrepreneur may be located in the area by applying to the director company responsible from management of the TDA, fulfilling the related and administrative procedures and in case the TDA facilities enable so.

There is no obstacle for the sponsors and for the contractual research organizations (CRO), who provide supportive services to sponsors in the clinical trial procedures, to be an entrepreneur in the TDA as long as they proceed with the conditions set forth by the TDA. Besides, it is known that there are such companies established within the TDAs.

According to provisional Article 2 of the TDA Law, regardless of the date of initialization of the activity, the profits acquired from the software and R&D activities of the entrepreneurs active in the TDA are excluded from the income and corporate tax until 31 December 2013. It must be mentioned that, it is not important whether or not the tax payer is a foreign-based or a full fledged taxpayer and is subjected to income tax or corporate tax in order to benefit from such exception. Therefore, the entrepreneurs who are active within the TDA and research personnel supporting the R&D activities may benefit from several taxational and non-taxational fosterages arising from the TDA Law.

Also, the income acquired from other activities carried outside the area by the tax payers active in the area will not be able to benefit from this exception even if they have been acquired from software development and R&D activities. In case the entrepreneurs are active with similar activities outside the area, this income will not benefit from the income exception provided with this provision.


Article 4 of the Regulation on TDA Implementation ("TDA Regulation") provides the definition of the researcher personnel, software developer personnel and R&D personnel. TDA Law and Regulation stipulate provisions concerning the fosterages provided to the R&D personnel who falls within these definitions.

It will be possible for particularly the part time working doctor or the dentist working in the clinical trials center and the personnel working at the hospital or similar centers established within the TDA and which the TDA enables to make clinical trials, to benefit from the fosterages provided with the TDA provisions.

As known, the salaries to be paid to the public corporations and the institutions which act as an investigator at a clinical trial and the university personals as a result of their contribution to a clinical trial, can only be paid by the pharmaceutical companies upon the approval in scope of the budgets submitted to the Ministry of Health and the Ethnic Boards. The salaries could only be paid to the revolving funds in the university hospitals and to the Ministry of Health funds in the public hospitals. This brings up one of the much argued issues in agenda. Thus, with the TDA Law, incomes that the part time working faculty members, faculty personnel, fellow investigator and experts will obtain in result of their services as a Researcher Personnel, are excluded from the scope of the university revolving funds. Besides, the faculty members will be able to establish companies in these areas or become a partner of a previously established company and/or take part in management of these companies in the aim of commercializing the outcome of the researches they have conducted upon the allowance of the University Administrative Board. Besides, in accordance with provisional Article 2 of the TDA Law, the salaries of the researcher, software programmer and R&D personnel who have contributed to the TDA activities are excluded from all means of tax until 31 December 2013.


The TDA Law and the TDA Regulation does not regulate cooperation of TDAs, and does not restructure TDAs as separate areas from each other. Besides, it is clearly stated that the activities outside the TDA cannot benefit from the fosterages that are provided with the Law. In this regard, in the multi-centered activities carried out in different TDAs and centers that are not within a TDA, situations like working with different service providers, preparing different budgets, making different distribution of tasks and pursuits for process will have to be conducted. Therefore TDAs may not be the most appropriate places for multi-centered activities.

In order to overcome these difficulties, it is important for the actors of the clinical trials to work in cooperation with each other. It is also aimed in the Pre-Accession Economic Program 2008 to make some attempts in order to achieve university-industry cooperation and endorsement of the R&D activities. In this regard, it seems possible to provide same quality and efficiency for single or multi centered clinical trials that are in the scope of the R&D activities carried out by the Ministry of Health, administrative organizations, director companies and other actors together in the TDA. In the future it is expected to make new regulations that will ensure new fields of work and motivation to the young and smart human resource that is required to support clinical and pre-clinical trials.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.